Safety and efficacy of Glecaprevir/Pibrentasvir combination therapy for chronic hepatitis C - including hemodialysis patients
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2019
Price : $35 *
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 14 Oct 2019 Results published in the Journal of Gastroenterology and Hepatology.
- 12 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 09 Sep 2019 Planned number of patients changed from 400 to 1500.